GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

azvudine   Click here for help

GtoPdb Ligand ID: 13479

Synonyms: RO-0622
Compound class: Synthetic organic
Comment: Azvudine is a nucleoside analogue that was first identified as an inhibitor of the HIV-1 RNA-dependent RNA polymerase (RdRp) [4]. It has more recently been reported to inhibit RdRp from the SARS-CoV-2 betacoronavirus [5]. The active triphosphate metabolite concentrates in the thymus and peripheral blood mononuclear cells, and oral treatment induces curative mechanisms in preclinical models.

azvudine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 120.74
Molecular weight 286.22
XLogP -1.43
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CN([C@H]2[C@H]([C@@H]([C@](CO)(N=[N+]=[N-])O2)O)F)C(=O)N=C1N
Isomeric SMILES C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)F
InChI InChI=1S/C9H11FN6O4/c10-5-6(18)9(3-17,14-15-12)20-7(5)16-2-1-4(11)13-8(16)19/h1-2,5-7,17-18H,3H2,(H2,11,13,19)/t5-,6-,7+,9+/m0/s1
InChI Key KTOLOIKYVCHRJW-XZMZPDFPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Azvudine was advanced to clinical evaluation for efficacy in the treatment of SARS-CoV-2 infection (COVID-19).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05689034 Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness Phase 2/Phase 3 Interventional Peking Union Medical College Hospital
NCT05033145 Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected) Phase 3 Interventional HRH Pharmaceuticals Limited In patients with mild COVID-19 symptoms, azvudine treatment accelerated the elimination of the virus and hastened recovery. 2
NCT04668235 Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected) Phase 3 Interventional HRH Pharmaceuticals Limited 3